Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (BHC) and Belgian skincare company YUN are expanding their strategic collaboration to Mexico and additional EMEA markets following a 2025 launch in Poland.
In Poland, Bausch Health broadened its dermatology portfolio to include YUN's eczema-prone skincare solutions alongside existing acne-prone products. Geographic rollout now covers YUN's acne- and eczema-prone skincare in the Czech Republic, Slovakia, Ukraine and Bulgaria, with YUN skincare also introduced in Mexico. The companies expect the next launch phase in Kazakhstan in October 2026, aiming to increase access to science-led, microbiome-friendly probiotherapeutical skincare solutions.
Bausch Health (NYSE:BHC) and its aesthetics business, Solta Medical, announced that the next-generation Fraxel FTX skin resurfacing laser is now available to health care practitioners in Australia starting September 1, 2026. The system builds on more than 20 years of Fraxel technology, combining dual wavelengths (1550 nm and 1927 nm) to target both superficial and deeper skin layers for dermatologic procedures and skin resurfacing.
Key features include Intelligent Optical Tracking with AccuTRAC to support uniform energy delivery, an ergonomic handpiece reduced in size and weight, integrated cooling for patient comfort, a refreshed guided treatment interface, and an updated console design. According to Bausch Health, Fraxel FTX is indicated for multiple conditions, including actinic keratosis, lentigos, ephelides, dyschromia including melasma, periorbital wrinkles, acne scars and surgical scars, with detailed contraindications, warnings, and potential adverse events provided for safe clinical use.
Bausch Health (NYSE:BHC) and its dermatology business Ortho Dermatologics announced the 2026 recipients of the Aspire Higher Scholarship Program, which supports students treated for dermatologic conditions. Since 2013, the program has awarded 87 scholarships totaling over $1 million. For 2026, six students will each receive up to $10,000 for undergraduate or graduate studies, selected based on essays about their educational journeys and dermatologic care. The program offers Undergraduate Scholar Awards and Graduate Scholar Awards, recognizing students nationwide and highlighting the role of healthcare professionals in their treatment.
Bausch Health (NYSE: BHC) and its gastroenterology business Salix Pharmaceuticals announced the 2026 Salix Gastrointestinal Health Scholars Program winners. For the seventh consecutive year, the program is awarding 10 students living with gastrointestinal disease scholarships of $10,000 each to support higher education.
The 2026 scholars were selected from more than 450 applicants based on personal essays about how their GI conditions have shaped their educational paths and the role of health care providers in their journeys. Awards span three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and a Working and/or Single Parent's Scholar Award. According to Bausch Health, an independent panel evaluated all applications, and the program is intended to empower students to pursue academic goals with confidence and support.
Bausch Health (NYSE: BHC) announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb (NYSE: BLCO), effective August 5, 2026. Bausch + Lomb is described as a key asset of Bausch Health.
Additional directors Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi also joined the Bausch + Lomb board. They replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, who resigned without any stated disagreements with Bausch + Lomb. Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding about 87% of its outstanding common shares, and requested these board changes in line with its ownership position.
Bausch Health (NYSE:BHC) reported second quarter 2026 consolidated revenues of $2.85 billion, up 13% year over year on a reported basis and 11% on an organic (non-GAAP) basis. GAAP net income attributable to Bausch Health was $258 million, with diluted EPS of $0.68; adjusted EPS (non-GAAP) was $1.26, up 40% from $0.90.
Adjusted EBITDA (non-GAAP) rose to $1.08 billion, up 28%. Bausch Health excluding Bausch + Lomb delivered 16% reported revenue growth and 28% Adjusted EBITDA growth. Key segment growth included Salix revenue up 21%, Solta Medical up 38% (12% organic), and Bausch + Lomb up 9%. Cash from operating activities increased to $671 million, and cash and equivalents reached $1.83 billion. The company raised full-year 2026 revenue, Adjusted EBITDA, and Adjusted Cash Flows from Operations guidance for Bausch Health excluding Bausch + Lomb.
Bausch Health (NYSE:BHC) plans to release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026.
The company will host a live conference call and webcast at 5:00 p.m. U.S. EDT, with materials available beforehand on its investor relations website.
Bausch Health (NYSE:BHC) announced that Michael Goettler resigned from its Board of Directors, effective June 30, 2026, following his appointment as President and CEO of Knoa Pharma.
Bausch Health stated that his resignation was not due to any disagreement regarding its operations, policies or practices.
Bausch Health (NYSE:BHC) and its aesthetic business Solta Medical announced that flagship brand Thermage® received the prestigious AAA Well-Known Trademark Certification from the China Trademark Association.
This top-tier recognition, held by only 217 brands in mainland China, highlights Thermage's brand reputation, consumer confidence, and market influence built over more than a decade in China.
Bausch Health (NYSE:BHC) reported results of its 2026 Annual Meeting of Shareholders held on May 19, 2026. All 10 director nominees were elected, including new director Eiry W. Roberts, M.D., who will chair the Science and Technology Committee.
Shareholders approved, on a non-binding basis, executive compensation, and confirmed PricewaterhouseCoopers LLP as auditor until the 2027 annual meeting, authorizing the board to set auditor remuneration. Final vote totals will be disclosed in a Form 8-K filing.